The following antibodies were used: anti‐BET1 (SC‐136390, Santa Cruz), anti‐ERGIC‐53 (13364‐1‐AP, Proteintech) or (EPR6979, Abcam), anti‐GOSR2 (170003, Synaptic Systems), anti‐HA (12CA5, Roche),
anti‐GAPDH (CB1001, Millipore), SEC22b (A304‐601A, Bethyl Laboratories), anti‐Syntaxin‐5 (SC‐365124, Santa Cruz),
anti‐GM130(Cell Signaling; mouse), α‐GM130 (Abcam),
anti‐α‐Dystroglycan (IIH6C4, Millipore 05‐593) and α‐PDI (Sigma Aldrich), and α‐mouse and α‐rabbit (Cy2 and Cy3 from Dianonva). Mammalian expression plasmid was generated by gene synthesis (GeneArt
®, Regensburg, Germany) of the cDNA of the transcript variant 1 of BET1 (NM_005868) and cloning into the expression vector pFrog‐HA, resulting in an N‐terminal HA‐tagged version of BET1. For the yeast expression plasmid, cDNA of BET1 was amplified via PCR and cloned into pRS316. Variants were introduced by site‐directed mutagenesis using mutagenesis kits (New England Biolabs, Frankfurt am Main, Germany and Agilent, Waldbronn, Germany). All constructs were verified by sequencing.
Donkervoort S., Krause N., Dergai M., Yun P., Koliwer J., Gorokhova S., Geist Hauserman J., Cummings B.B., Hu Y., Smith R., Uapinyoying P., Ganesh V.S., Ghosh P.S., Monaghan K.G., Edassery S.L., Ferle P.E., Silverstein S., Chao K.R., Snyder M., Ellingwood S., Bharucha‐Goebel D., Iannaccone S.T., Dal Peraro M., Foley A.R., Savas J.N., Bolduc V., Fasshauer D., Bönnemann C.G, & Schwake M. (2021). BET1 variants establish impaired vesicular transport as a cause for muscular dystrophy with epilepsy. EMBO Molecular Medicine, 13(12), e13787.